Clinical Trials Logo

Filter by:
NCT ID: NCT06237881 Recruiting - Melanoma Clinical Trials

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Start date: January 31, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To learn if KSQ-001EX is safe to give to participants with advanced forms of solid tumors.

NCT ID: NCT06237868 Recruiting - Parkinson Disease Clinical Trials

rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease

Start date: May 2024
Phase: N/A
Study type: Interventional

This study's objective is to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC) of patients with Parkinson's Disease (PD) who experience impulse control disorders (ICDs) on impulse control symptoms and cognitive behaviors linked to ICDs: reinforcement learning and delay-discounting. This is a randomized sham-controlled cross-over trial. All patients will undergo a session of active rTMS and a session of sham rTMS, with the order of sessions randomized across participants. Following recruitment and eligibility screening, the eligible participants will undergo two sessions of rTMS (active and sham), immediately followed by neurocognitive tasks and questionnaires, no more than 1-2 weeks apart. Each session will have a duration of approximately 1-1.5 hours.

NCT ID: NCT06237855 Not yet recruiting - Ventral Hernia Clinical Trials

Investigating the Feasibility and Outcomes of Patient Self-Drain Removal After Ventral Hernia Repair

SDR
Start date: July 2024
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to teach patients to safely and effectively self-remove drains at home in adults (aged 18 and older) following a ventral hernia repair (VHR). Researchers will compare the group of subjects self-removing the drain at home to a control group of standard of care drain removal during a clinic visit by a provider to see if subjects are able to safely self-remove the drain at home.

NCT ID: NCT06237829 Recruiting - Blindness Clinical Trials

Testing Tactile Aids With Blind Subjects

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The objective of this project is to create richer tactile aids by using materials chemistry to create tactile sensations in tactile aids, as an alternative to traditional physical bumps, lines, or textures. These materials are commonly used in household products, but have not yet been used to enrich tactile aids. Successful outcomes are primarily the accuracy with which low vision or blind subjects identify objects made from tactile coatings versus traditional tactile aids. Other outcomes include time to completion of the task, or the number of distinctive categories that participants can identify.

NCT ID: NCT06237621 Recruiting - Clinical trials for Peripheral Arterial Disease

Using SnapshotNIR With Provocative Leg Maneuver for PAD Assessment

Start date: January 2024
Phase:
Study type: Observational

The objective of this trial is to determine if Near-infrared spectroscopy (NIRS) can accurately evaluate the degree of Peripheral Arterial Disease (PAD) during a Provocative Elevation Maneuver of the Lower Extremity (PEMLE) test, as compared to routine clinical assessments.

NCT ID: NCT06237465 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Botulinum Toxin-A for Hidradenitis Suppurativa

Start date: April 2024
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to determine if the medication Botulinum Toxin-A (BTX-A) is effective in treating hidradenitis suppurativa (HS)

NCT ID: NCT06237452 Recruiting - Clinical trials for Clostridium Difficile

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

RESTORATiVE303
Start date: May 20, 2024
Phase: Phase 3
Study type: Interventional

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).

NCT ID: NCT06237322 Not yet recruiting - Diabetes Clinical Trials

Study of RE.DOCTOR Vitals® Software Accuracy

RE-VITAL
Start date: March 1, 2024
Phase:
Study type: Observational

The purpose of this observational trial is to advance digital health monitoring through the analysis of Photoplethysmography (PPG) waveforms collected via RE.DOCTOR Vitals software. The study aims to collect a diverse and extensive dataset of PPG waveforms, alongside traditional physiological measurements, for the purpose of enhancing existing algorithms and machine learning models used in health monitoring. The primary focus is on improving the accuracy and reliability of algorithms in interpreting PPG data to derive meaningful insights into physiological parameters. The main questions it aims to answer are: - How can extensive datasets of PPG waveforms be utilized to enhance existing algorithms and machine learning models? - How do correlations between PPG waveforms and key physiological parameters (such as glucose levels, blood pressure, heart rate, respiration rate) contribute to refining algorithms for more accurate and reliable health predictions? Participants will be asked to: - Continuously monitor their health using smartphone applications. - Allow the collection of PPG waveforms in diverse settings. - Engage in tasks related to monitor health parameters using medically approved devices

NCT ID: NCT06237296 Recruiting - Healthy Volunteers Clinical Trials

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Start date: January 23, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older. Treatment: - RSV/hMPV mRNA / LNP 1 at 3-4 different doses or, - RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or, - RSV mRNA / LNP 1 at 1 dose or, - hMPV mRNA / LNP 1 at 1 dose

NCT ID: NCT06237179 Recruiting - Prostate Cancer Clinical Trials

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

EXTRA-PC
Start date: February 21, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak & 6-minute walk distance [6MWD]) among prostate cancer (PC) patients compared to controls receiving healthy living education (HLE) at 12 weeks.